A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients With Primary Sclerosing Cholangitis
Latest Information Update: 18 Oct 2024
At a glance
- Drugs Volixibat (Primary)
- Indications Intrahepatic cholestasis; Primary sclerosing cholangitis
- Focus Registrational; Therapeutic Use
- Acronyms VISTAS
- Sponsors Mirum Pharmaceuticals
- 17 Jun 2024 According to a Mirum Pharmaceuticals media release, interim analysis for the VISTAS PSC study was conducted and the independent data review committee recommended that the study continue with the selected volixibat dose of 20 mg twice daily, with no changes to the study. The criteria for continuation included safety as well as a predefined threshold for efficacy. The sponsor and investigators are blinded to the interim results and analysis.
- 17 Jun 2024 According to a Mirum Pharmaceuticals media release, the company to host a conference call to discuss a interim analysis of VISTAS and VANTAGE on Monday, June 17 at 8:30 a.m. ET/5:30 a.m. Kris Kowdley is investigator in this trial.
- 08 May 2024 According to a Mirum Pharmaceuticals media release, interim analysis expected in June of 2024.